Amedisys Reports Fourth Quarter and Year End 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Google defeats US bid to force ad tech sale
Amedisys (AMED) Misses Q4 EPS by 2c, Offers Guidance
February 27, 2018 5:03 PM ESTAmedisys (NASDAQ: AMED) reported Q4 EPS of $0.56, $0.02 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $404.2 million versus the consensus estimate of $394.62 million.
GUIDANCE:
Amedisys sees FY2018 EPS of $2.97-$3.08, may not compare to the consensus... More
